Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples

Lampros Dimitrakopoulos1, Panagiotis A Vorkas13, Vasilis Georgoulias2 and Evi S Lianidou1*

Author affiliations

1 Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, 15771, Greece

2 Department of Medical Oncology, University General Hospital of Heraklion, PO BOX 1352, Crete, 71110, Greece

3 Present address: Biomolecular Medicine, Department of Surgery and Cancer, Imperial College London, London, SW7 2AZ, UK

For all author emails, please log on.

Citation and License

BMC Cancer 2012, 12:486  doi:10.1186/1471-2407-12-486

Published: 22 October 2012

Abstract

Background

CST6 promoter is highly methylated in cancer, and its detection can provide important prognostic information in breast cancer patients. The aim of our study was to develop a Methylation-Sensitive High Resolution Melting Analysis (MS-HRMA) assay for the investigation of CST6 promoter methylation.

Methods

We designed primers that amplify both methylated and unmethylated CST6 sequences after sodium bisulfate (SB) treatment and used spiked control samples of fully methylated to unmethylated SB converted genomic DNA to optimize the assay. We first evaluated the assay by analyzing 36 samples (pilot training group) and further analyzed 80 FFPES from operable breast cancer patients (independent group). MS-HRMA assay results for all 116 samples were compared with Methylation-Specific PCR (MSP) and the results were comparable.

Results

The developed assay is highly specific and sensitive since it can detect the presence of 1% methylated CST6 sequence and provides additionally a semi-quantitative estimation of CST6 promoter methylation. CST6 promoter was methylated in 39/80 (48.75%) of FFPEs with methylation levels being very different among samples. MS-HRMA and MSP gave comparable results when all samples were analyzed by both assays.

Conclusions

The developed MS-HRMA assay for CST6 promoter methylation is closed tube, highly sensitive, cost-effective, rapid and easy-to-perform. It gives comparable results to MSP in less time, while it offers the advantage of additionally providing an estimation of the level of methylation.

Keywords:
Methylation-sensitive high-resolution melting analysis; Cystatin M; CST6; DNA methylation; Breast cancer; Methylation specific PCR